- Home
- KOD vs NOAH Comparison
KOD vs NOAH Comparison
Compare KOD & NOAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | NOAH |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | China |
| Employees | 121 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 754.2M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | KOD | NOAH |
|---|---|---|
| Price | $23.19 | $11.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $28.29 | $10.75 |
| AVG Volume (30 Days) | ★ 503.1K | 127.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.11% |
| EPS Growth | ★ 32.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.79 |
| P/E Ratio | ★ N/A | $13.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $7.67 |
| 52 Week High | $31.18 | $12.84 |
Technical Indicators
Market Signals| Indicator | KOD | NOAH |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 43.91 |
| Support Level | $21.19 | $11.11 |
| Resistance Level | $29.17 | $12.41 |
| Average True Range (ATR) | 1.70 | 0.36 |
| MACD | -0.35 | -0.07 |
| Stochastic Oscillator | 8.59 | 20.75 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About NOAH Noah Holdings Limited
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.